Chemistry & Biology · 2015 · 88 citations · 36 references
MedicineMedicinal ChemistryPharmacologyDrug DiscoveryMetabolismMolecular PharmacologyEnzyme InhibitionPulmonary TuberculosisTuberculosis PharmacotherapyBiochemical CharacterizationDrug-resistant PathogensMetabolomic ScreeningMolecular Drug ResistanceMycobacterium Tuberculosis InfectionPhenotypic Drug Susceptibility TestingPhenotypic Screening AnalysisTuberculosis Drug Resistance
To combat the emergence of drug-resistant strains of Mycobacterium tuberculosis, new antitubercular agents and novel drug targets are needed. Phenotypic screening of a library of 594 hit compounds uncovered two leads that were active against M. tuberculosis in its replicating, non-replicating, and intracellular states: compounds 7947882 (5-methyl-N-(4-nitrophenyl)thiophene-2-carboxamide) and 7904688 (3-phenyl-N-[(4-piperidin-1-ylphenyl)carbamothioyl]propanamide). Mutants resistant to both compounds harbored mutations in ethA (rv3854c), the gene encoding the monooxygenase EthA, and/or in pyrG (rv1699) coding for the CTP synthetase, PyrG. Biochemical investigations demonstrated that EthA is responsible for the activation of the compounds, and by mass spectrometry we identified the active metabolite of 7947882, which directly inhibits PyrG activity. Metabolomic studies revealed that pharmacological inhibition of PyrG strongly perturbs DNA and RNA biosynthesis, and other metabolic processes requiring nucleotides. Finally, the crystal structure of PyrG was solved, paving the way for rational drug design with this newly validated drug target.
36
Wolfgang Kabsch · Acta Crystallographica Section D Biological Crystallography · 2010 · 16.9K citations · Full text
Global tuberculosis report (2014)
L.A. Gabbasova, E.R. Experts Who · 2014 · 13.2K citations
Overview of the<i>CCP</i>4 suite and current developments
Martyn Winn, Charles Ballard, Kevin Cowtan et al. · Acta Crystallographica Section D Biological Crystallography · 2011 · 12.6K citations · Full text